Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | CSGALNACT1 | Q8TDX6 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297539 | 1.00 | CXCR1 (0.44) | CXCR1SMN1; SMN2RAB9ACSGALNACT1MAPT | |
| SCHEMBL2296907 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ACSGALNACT1MAPTLMNA | |
| SCHEMBL2296905 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ACSGALNACT1MAPTLMNA | |
| SCHEMBL2296315 | 0.79 | CSGALNACT1 (0.59) | CSGALNACT1MAPTMEN1KMT2A | |
| SCHEMBL2296314 | 0.79 | CSGALNACT1 (0.59) | CSGALNACT1MAPTMEN1KMT2A | |
| SCHEMBL2294233 | 0.79 | CSGALNACT1 (0.54) | CSGALNACT1 | |
| SCHEMBL2294231 | 0.79 | CSGALNACT1 (0.54) | CSGALNACT1 | |
| SCHEMBL1761338 | 0.79 | POLB (0.43) | SMN1; SMN2RAB9AMAPTMEN1GAA | |
| SCHEMBL3235739 | 0.76 | CSGALNACT1 (0.53) | CSGALNACT1 | |
| SCHEMBL3235913 | 0.75 | CSGALNACT1 (0.50) | CSGALNACT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835428-B2 | Diacylglycerol acyltransferase inhibitors | Piramal Enterprises Limited (IN) | 2014-09-16 | — | — | US | disclosed |
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED. | 2011-08-11 | — | — | US | disclosed |
| WO-2010023609-A1 | OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | CXCR1 4237/4885SMN1; SMN2 4532/4885RAB9A 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.